Clinical trials: First Pregnancy
Incomplete Abortion
400mcg Sublingual Misoprostol as First Line Treatment
Women presenting with incomplete abortion and eligible for treatment with misoprostol were offered 400mcg sublingual misoprostol for treatment.
- Trial name
- NCT01939457
- Testing
- Misoprostol
- Where
- Senegal
- Volunteers
- 641 people, healthy volunteers welcome
- Sponsor
- Gynuity Health Projects
Urothelial Carcinoma, Anlotinib
Anlotinib Combined With Platinum/Gemcitabine for First Line Treatment of Advanced Urothelial Carcinoma
Anlotinib is a novel oral multitarget tyrosine kinase inhibitor and primary targeted to VEGFR, FGFR, PDGFR and c-Kit. This study intends to assess the efficacy and safety of anlotinib combined with platinum/gemcitabine for first…
- Conditions
- Urothelial Carcinoma, Anlotinib, Urogenital Neoplasms, Cisplatin
- Trial name
- NCT05030077
- Testing
- Anlotinib, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Tianjin Medical University Second Hospital
Chronic Kidney Disease(CKD), Genetic Kidney Disease
Genomic First Testing in Chronic Kidney Disease
This multi-center study examines the role of genetic testing in patients with chronic kidney disease (CKD) who are identified as being at risk for genetic kidney disease, based on Ontario Health's Provincial Genetic Program…
- Trial name
- NCT06794567
- Testing
- Genetic Testing
- Where
- Canada
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Dervla Connaughton
Pregnancy, Previous Cesarean Section
Survey of Women's Choice of Delivery Before Consulting With Her Obstetrician
We are surveying women who have had a previous cesarean section at the time of entry into prenatal care for their next pregnancy about their thoughts related to a trial of labor after cesarean (TOLAC) or repeat c-section.
- Trial name
- NCT02010671
- Testing
- Survey
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Davis
Multiple Myeloma
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
The purpose of this study is to determine the efficacy and safety of targeted BCMA CART cells secreting PD1 and interleukin 21 fusion protein immunotherapy for first-line consolidation therapy of multiple myeloma with renal…
- Trial name
- NCT07489534
- Testing
- PD-1Ab21-BCMA CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Daihong Liu
Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's…
- Conditions
- Clear Cell Renal Cell Carcinoma, Prognostic Cancer Model, Recurrent Renal Cell Cancer
- Trial name
- NCT06088134
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Mingzhao Xiao
Ovarian Cancer, Primary Peritoneal Carcinoma
Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels
The purpose of this study is to determine whether injections of Å6 are effective in treating ovarian cancer patients who have completed first-line therapy and currently have no detectable cancer but have experienced a doubling of…
- Trial name
- NCT00083928
- Testing
- Å6 subcutaneous injection
- Where
- 24 sites in United States
- Volunteers
- 60 people
- Sponsor
- Ångstrom Pharmaceuticals
Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC)
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or…
- Conditions
- Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
- Trial name
- NCT07188896
- Testing
- Fianlimab, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Brian Rini
Melanoma, Breast Cancer
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
The primary objective is to determine the safety and tolerability of the novel compound, MRx0518 in patients with solid tumours at 30 days post-surgery.
- Conditions
- Melanoma, Breast Cancer, Uterine Cancer, Ovarian Cancer
- Trial name
- MICROBIOME (NCT03934827)
- Testing
- MRx0518 Capsules
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Imperial College London
Catheter Blockage, Oncology
A Novel Ureteric Stent in Kidney Stone Patients and Oncology Patients Compared to a Conventional JJ Stent
Urological stents and catheters often lead to inflammation, causing pain and infection in the urinary tract. Moreover, 80% of stents are associated with pain, negatively impacting on QoL and mental health.
- Conditions
- Catheter Blockage, Oncology, Kidney Stone
- Trial name
- CASSETTE (NCT06815120)
- Testing
- Experimental ureteric stent with specially shaped side-holes that prevent stagnation points (i.e., areas of low flow that cause particles to settle and E&B), Qualitative interview
- Where
- 2 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Southampton
Metastatic Cancer, Metastatic Breast Cancer
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
CHANCES-IPC 2021-008 is First In Human, Phase I, multicenter, European study evaluating an anti-CD73, IPH5301 in advanced and/or metastatic cancer.
- Conditions
- Metastatic Cancer, Metastatic Breast Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- CHANCES (NCT05143970)
- Testing
- IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Institut Paoli-Calmettes
Transitional Cell Carcinoma of Bladder
PF-03446962 in Relapsed or Refractory Urothelial Cancer
Salvage chemotherapy for advanced urothelial cancer (UC) yields suboptimal response rates of 15-40%, a median progression-free survival of 2-4 months and a median overall survival of 6 months.
- Trial name
- NCT01620970
- Testing
- PF03446962
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Gestational Diabetes
To Identify Urinary Biomarkers Associated With Gestational Diabetes Mellitus [GDM]
Gestational diabetes mellitus(GDM) is one of the most common complications of pregnancy. The incidence of GDM is higher in Asian than in other regions, and GDM can increase the risk of a series of perinatal complications.
- Trial name
- NCT05992974
- Where
- 2 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Threatened Miscarriage in First Trimester
Value of CA125 and Yolk Sac Morphology in Prediction of Pregnancy Outcome in Threatened Miscarriage
evaluation of serum CA125 level and yolk sac morphology in women with threatened miscarriage is very important to predict pregnancy outcome
- Trial name
- NCT03320213
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Ovarian Tumors
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
The study consists of two parts based on the administration of single-agent GRN-300 or in combination with paclitaxel. Part 1 (Phase IA) will test the tolerability of continuous twice a day dosing of oral GRN-300, a…
- Trial name
- NCT04711161
- Testing
- GRN-300, Paclitaxel
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Green3Bio, Inc.
Uterine Hemorrhage
Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS) Abnormal Uterine Bleeding Safety Study
Abnormal uterine bleeding (AUB) is defined as "flow outside of normal volume, duration, regularity, or frequency". Acute AUB is excessive bleeding that requires immediate intervention to prevent further blood loss.
- Trial name
- AQTH-EA-22 (NCT07580560)
- Testing
- Aqua Therapeutics Thermal Therapy Vapor Ablation System (ATTTVAS)
- Where
- 3 sites in Italy, Netherlands
- Volunteers
- 10 people
- Sponsor
- Aqua Therapeutics, Inc.
Ovarian Cancer
Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1
The purpose of this study is to evaluate INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary…
- Trial name
- MAESTRA 3 (NCT07797283)
- Testing
- INCB123667, Bevacizumab
- Volunteers
- 590 people
- Sponsor
- Incyte Corporation
Preeclampsia
Optimizing the Use of Aspirin for the Prevention of Preeclampsia
Pregnant women at higher risk for preeclampsia (PE) are currently recommended to take low-dose aspirin (acetylsalicylic acid, ASA) daily from the first trimester until 36 weeks of gestation.
- Trial name
- Optim-PRE (NCT07665853)
- Testing
- Discontinuation of Acetylsalicilic acid 150 mg/day at 24-28 weeks of gestation
- Where
- 38 sites in Austria, Bulgaria and 5 more
- Volunteers
- 15,160 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Cervical Cancer, Recurrent Cervical Cancer
Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer
Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis…
- Conditions
- Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer
- Trial name
- NCT07673211
- Testing
- Biospecimen collection (peripheral blood and paraffin tumor tissue)
- Volunteers
- 60 people
- Sponsor
- Zhejiang Cancer Hospital
Miscarriage, Preterm Birth
Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial
Miscarriages and preterm births are common and serious events affecting women, families, and healthcare systems on many levels. One of the risk factors for miscarriage and preterm birth is bleeding in the first trimester of…
- Trial name
- NCT02145767
- Testing
- Progesterone
- Where
- 7 sites in Canada
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.